Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
  • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
  • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a method for treating neurodegenerative conditions, particularly those in which increase in transforming growth factor ⁇ (TGF- ⁇ ) is beneficial, particularly TGF- ⁇ l . More particularly the present invention provides treatment for conditions such as multiple sclerosis and the degenerative sequelae associated with head trauma, stroke and intracranial bleeds, whereby neuronal function is improved or restored from an impaired condition. Further provided are novel use of known and novel compounds comprising unsaturated fatty acid moieties for the manufacture of medicaments capable of effectively treating such conditions, more particularly being capable of achieving previously unattained levels of success with regard to recovery of neurological function.
• MS multiple sclerosis
• MS patients have a much higher number of neuro- antigen e.g. myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) autoreactive T-cells which are in an increased state of activation compared with healthy controls [Fredrikson et al 1994, Keriero de Rosbo et al 1993, 1997, Chou et al 1992, Ota et al 1990, Burns et al 1999, Zhang et al 1994, Tejada-Simon et al 2001].
• MBP myelin basic protein
• MOG myelin oligodendrocyte glycoprotein
• axonal damage e.g. chronic inflammation, demyelination and astrogliosis in MS is complex but white matter inflammation and demyelination are considered to determine disease severity, whilst recent studies suggested that axonal damage in MS begins in the early stages of the disease and contributes to disability (De Stefano et al, 2001).
• EAE Experimental autoimmune encephalomyelitis
• TGF- ⁇ and PGE 2 production has been shown to be increased non-specifically in ⁇ -linolenic acid fed mice ex vivo; but whilst TGF- ⁇ has been reported to protect in acute and relapsing EAE ((Racke et al (1993); Santambrogio et al (1993)), PG inhibitors such as indomethacin augment, and thus worsen, the disease (Ovadia & Paterson (1982)).
• Cytokines are implicated in the pathogenesis of MS, with many studies showing an increase in myelinotoxic inflammatory cytokines (TNF- ⁇ , IL-l ⁇ and IFN- ⁇ ) coinciding with the relapse phase of the disease.
• TGF- ⁇ 1 levels of the anti- inflammatory and immunosuppressive cytokine transforming growth factor-betal (TGF- ⁇ 1) appear to be reduced during a phase of relapse and increase as the patient enters remission.
• TGF- ⁇ 1 levels of the anti- inflammatory and immunosuppressive cytokine transforming growth factor-betal
• TGF- ⁇ -secreting T-cells inhibit EAE effector cells
• TGF- ⁇ is expressed in the CNS and, in oral-tolerance-induced protection in EAE, TGF- ⁇ and PGE 2 are expressed in the brain (Karpus & Swanborg (1991); Khoury et al (1992)). Harbige ((1998) concluded that dietary ⁇ -linolenic acid effects on EAE are mediated through Th -like mechanisms involving TGF- ⁇ and possibly through superoxide dismutase antioxidant activity.
• Borage oil (typically 23% ⁇ -linolenic acid and 37% linoleic acid per 100% fatty acid content) has been shown to significantly reduce clinically important signs and symptoms of autoimmune disease associated with active rheumatoid arthritis (Leventhal et al (1993)). Borage oil and fungal oil (see Figure 1) have been shown to be effective in the EAE animal model use to identify MS candidates, whilst never having been shown to be significantly effective in the human disease.
• T cell depleters and modulators such as cyclophosphamide
• T-cells indeed produce beneficial cytokines, such as TGF- ⁇ 1, as well as deleterious ones in man.
• David Baker of Institute of Neurology UK summed up the disparity between what is effective in the EAE and in MS with a paper entitled 'Everything stops EAE, nothing stops MS' at the 10 th May 2004UK MS Frontiers meeting of the UK MS Society. It is clear that immunosuppression alone cannot cure MS.
• Avonex ®, Rebif ® and other interferon preparations This gold standard treatment only addresses needs of some, eg 30%, of the patients and even in these symptom improvement is restricted to reduced severity of relapses. Whilst symptoms may be reduced in a proportion of patients, the disease tends to progress to further disability and death due to underlying degeneration.
• the present inventors have now surprisingly determined that with compliance to a Tiigh dose' treatment with triglyceride oil containing ⁇ -linolenic acid with suitable accompanying fatty acid content, remarkable levels of improvement in almost all symptoms of MS can be achieved, way surpassing that provided by the present gold standard treatment. Such success is particularly surprising in the light of the prior use of other ⁇ -linolenic acid containing preparations without such significant success.
• PBMC peripheral blood mononuclear cell production
• pro-inflammatory cytokines TNF- ⁇ and IL-l ⁇ were significantly and markedly ( ⁇ 70%) reduced and they either maintained or increased the PBMC membrane long chain omega-6 fatty acids dihomo- ⁇ -linolenic acid (DHLA) and arachidonic acid (AA) in contrast to patients taking placebo who demonstrated loss of these fatty acids over the course of the trial period.
• DHLA dihomo- ⁇ -linolenic acid
• AA arachidonic acid
• a triglyceride oil comprising triglycerides of both ⁇ -linolenic acid and linoleic acid with specific positional distribution within the triglyceride molecules, preferably with oleic acid, can provide significant decreasing EDSS score in multiple sclerosis patients over a number of months and years, a result that is unattainable with any of the currently administered therapies.
• ⁇ -Linolenic acid (18:3n-6, GLA) is known to be rapidly converted to longer- chain omega-6 polyunsaturated fatty acids dihomo- ⁇ -linolenic acid and arachidonic acid in vivo (Phylactos et al 1994, Harbige et al 1995, 2000). Therefore to increase the level of membrane long chain omega-6 fatty acids in MS the inventors have reviewed results obtained with several GLA-containing oils:- both fungal (from Mucor iavanicus) and plant (Borago officianalis). Evening primrose Oenothera spp.
• EAE Experimental autoimmune encephalomyelitis
• CREAE chronic relapsing experimental autoimmune encephalomyelitis
• EAE is an autoimmune inflammatory disease of the CNS, with or without demyelination, inducible in rodents and other mammalian species.
• MOG myelin oligodendrocyte glycoprotein
• blackcurrant seed oil 72 % w/w 18:3n-6, GLA
• blackcurrant seed oil has a low sn-2 GLA with most of the GLA in the sn-1 and sn-3 positions (Lawson and Hughes 1988).
• TG-GLA structured triacylgcerol containing three GLA's
• Boage Oil contains other constituents that interfere with GLA activity.
• the present inventors used a borage oil that was selected with the highest sn-2 GLA for trial purposes (>40%) - compared with lower amounts in other samples that were available at the time.
• Blackcurrant seed oil which at the time was available in relative large quantities was not considered optimal because of it's low sn-2 GLA content.
• a further selection criterion was that the level of total long chain monoenoic fatty acids be kept below 5%.
• the trial oil contained only natural levels of vitamin E (0.05 mg/g) with no additionally added vitamin E as is routinely the case with commercial borage seed oils (e.g. 1 mg/g).
• a method of treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of an oil containing both ⁇ -linolenic acid and linoleic acid residues as triglyceride ester, the ratio of ⁇ -linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ⁇ -linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF- ⁇ levels in the patient to therapeutic levels.
• therapeutic levels levels at least consistent with healthy subjects.
• the dose is such as to produce a TGF- ⁇ l/TNF- ⁇ ratio in blood of a patient, after 18 months of daily dosing, of 0.4 to 3.0, at least 0.5, more preferably at least 0.75 and most preferably at least 1.
• the dose is such as to produce a TGF- ⁇ l/TL-l ⁇ ratio in blood of a patient, after 18 months of daily dosing, of at least 0.5, more preferably at least 0.75 and most preferably at least 1.
• said levels are produced after 12 months and more preferably after 6 months.
• the amount of oil administered daily will be between 3 and 30 grams, orally dosed, still more preferably between 5 and 20 grams and most preferably between 7 and 18 grams, typically 15 grams.
• the oil in addition to the ⁇ -linolenic acid and linoleic acid fatty acid residues, the oil includes an esterified fatty acid that is non-structural, ie. that is metabolised to produce energy, such as oleic acid residues.
• residue is meant the moiety that remains after the fatty acid carboxyl group esterifies to one of the hydroxy groups of the glycerol molecule.
• the oil administered is an oil source from Borage oil or a fungal oil eg. eg from Mucor iavanicus.
• Typical Borage oil and fungal oil compositions are illustrated in Table 1 wherein 18:2n-6 and 18:3n-6 represent linoleic and ⁇ -linolenic acid residue by percent respectively.
• Borage oils typically contain from 20 to 25% ⁇ -linolenic acid residues as percentage of fatty acid residues in the oil and from 35 to 40% linoleic acid residues.
• Preferred Borage oils are those in which the amount of esterified ⁇ -linolenic acid at the sn-2 position is at least 35% of fatty acid residues at that position, more preferably greater than 39% and still more preferably greater than 40%. Most preferred oils are over 41%), such as 42 to 44% sn-2 GLA, whilst ideally they will be over 45%. As stated by Huang et al above, 60% sn-2 GLA Borage Oils have been produced and should be available for selection.
• the sn-1 and sn-3 position residues are preferably linoleic, oleic and ⁇ -linolenic acid residues, with preferred oils having relatively high oleic acid content in at least one, if not both, of these positions, eg, in excess of 12%, more preferably in excess of 14%>.
• a typical Borage oil suitable for use in the use of the present invention has fatty acid distribution as follows
• Sn-1 14% 18:1 (Oleic), 54% 18:2n-6 (linoleic) and 4% 18:3n-6 ( ⁇ -linolenic)
• Sn-2 14% 18:1 (Oleic), 42% 18:2n-6 (linoleic) and 40% 18:3n-6 ( ⁇ -linolenic) Sn-3: 19% 18:1 (Oliec), 18% 18:2n-6 (linoleic) and 30% 18:3n-6 ( ⁇ -linolenic)
• the total amount of ⁇ - linolenic acid residues may be lower than for Borage oil as long as the sn-2 ⁇ - linolenic acid: linoleic acid ratio is at least 0.8, more preferably greater than 1.
• fungal oils tend to have more 'metabolic' directed oleic acid residues than linoleic acid residues.
• preferred fungal oils are those in which the amount of esterified ⁇ -linolenic acid at the sn-2 position is at least 18% of fatty acid residues at that position, more preferably at least 20%> and most preferably at least 22%>.
• Preferred fungal oils have in excess of 45%> of the sn-2 fatty acid residues as oleic acid residues, more preferably in excess of 50%o.
• Sn-1 25% 18:1 (Oleic), 5% 18:2n-6 (linoleic) and 13% 18:3n-6 ( ⁇ -linolenic)
• Sn-2 54% 18:1 (Oleic), 19% 18:2n-6 (linoleic) and 20% 18:3n-6 ( ⁇ -linolenic)
• Sn-3 40% 18:1 (Oliec), 3% 18:2n-6 (linoleic) and 20% 18:3n-6 ( ⁇ -linolenic)
• oils will need to be sourced by testing for the percentage of said fatty acids at each position as an average over the many triglycerides in a give oil mix.
• Such is well within the skill of those in the art, such as eg. Mylnefiled Research Services Ltd, Lipid Analysis Unit, Mylnefiled, Inverghowrie, Dundee DD2, 5DA, Scotland UK.
• the applicants have managed to source a number of such oils meeting the criteria set out above, the highest sn-2 figures ofabout 46% being found for example in New Zealand sourced oils in 2003: this of course may vary from year to year.
• a further NMR method for analysis of such oils in a selection process is provided in the methods section below. It will however be realised that should all oils available at a given tiem be below the 35% sn-2 GLA figure, and preferaby if they are below 40 or 45%>, supplementation with a synthetic triglyceride or tryglyceride mix will be possible.
• a numebr of suitable lipids are known in the art and may for example be isolated or combined mixtures of LGL, OGO, OGL, LGO or other components known to be present in Borage Oil (see Table 3 of EP 0520624).
• TriGLA might be added (FR 2,617,161 (1988)), although it is preferred for the present purposes to keep the sn-1 and sn-2 position GLA levels from getting too high as that would un the risk of overly pro-inflammatory effect due to overflow into systemic GLA and thus DHGLA and then Arachidonic pools.
• Synthesis of OGO is for example taught in Y.-S. Huang, X. Lin, P. R. Redden and D. F. Horrobin, J Am. Oil Chem.Soc.,72,625-631(1995)In vitro Hydrolysis of Natural and Synthetic ⁇ -Linolenic Acid-Containing Triacylglycerols by Pancreatic Lipase and K. Osada, K.
• the amount of potentially toxic long chain monoenoic fatty acids such as erucic acid (22:ln-9) and other long chain monoenoic fatty acids i.e. 24:ln-9 (nervonic acid) and 20:ln-9 (gadoleic acid) are as low as possible, preferably lower than 5% of fatty acid residues, more preferably less than 3%o and more preferably less than 2%>.
• Another feature of a preferred oil is low or zero added vitamin E such that only natural levels of vitamin E (0.05 mg/g) is provided.
• Further aspects of the present invention provide use of triglyceride oils as described above for the manufacture of a medicament for the treatment of neurodegenerative disease, more specifically for the arresting of underlying neurodegeneration and the restoration of neuronal function.
• medicaments are for the normalising of neuronal membrane composition, the restoration of healthy TGF- ⁇ 1/TNF ⁇ ratios and the ratios of TGF- ⁇ 1 with other cytokines, the arresting of neurodegeneration in multiple sclerosis and the restoration, in part or completely, of neuronal function such as measured, eg. By MRI or CAT scan or by EDSS score.
• Such use will include treatment of cerebral impairment after stroke, head trauma and intracranial bleeding.
• oils for use in the present invention may be administered by any of the conventional vehicles known in pharmacy. Most conveniently they are administered as neat oils or in admixture with foodstuffs, in the form of capsules containing such oils, or in enterically coated forms. Other forms will occur to those skilled in the art as delivery technology advances. It will be realised by those skilled in the art that other beneficial agents may be combined with the oils for use in the present invention. These might be ion channel blcokers , eg.
• Table 1 Shows the compositional % Total fatty acid content of various triglyceride oils and protective effect in EAE.
• Table 2 Shows the parameters of the three treatment groups in high sn-2 GLA Borage Oil trial
• Table 3 Shows the effect of various forms of GAL on EAE incidence and clinical score in SJL mice.
• Table 4 Shows the failure of enriched Blackcurrent oil, a high GLA, but low sn-2- GLA, plant oil, to match fungal and Borage oils in EAE.
• Table 5 Shows the results analyses of four batches of trial Borage Oil particularly with respect of monoenes.
• Table 6 Shows an analysis of a non-trial oil particularly with respect to monoenes.
• Figure 1 Shows peripheral blood mononuclear cell cytokine production in placebo and trail oil treated human MS patients at 18 months.
• Figure 2 Shows the effect of placebo and low dose (5g/day) high sn-2 GLA Borage oil on human MS patient EDSS score as compared to high dose (15g/day) displayed as a histogram.
• Figure 3 Shows the effect of placebo, low dose and high dose high sn-2 GLA Borage oil on human MS patient EDSS displayed as a graph.
• Figure 4 Shows the effect of placebo, low dose and high dose high sn-2 GLA Borage oil on human MS patient Mean Relapse rate (%>) as a histogram
• Figure 5 Shows the effect of placebo, low dose and high dose high sn-2 GLA Borage oil on human MS patient Mean Relapse rate (%) as a graph.
• Figure 6 Shows the effect of linoleic acid: ⁇ -linolenic acid ratio of oils as compared to their protective effect on mice CREAE.
• the resolution of the nuclei in each environment is determined by the linewidth and the chemical shift differences between adjacent peaks .
• the area under the peak, arising from each nucleus is proportional to the number of nuclei in that environment because all 13 C exhibit the same absorption . Therefore, the chemical shift and the integrated area of each peak can be used for both qualitative and quantitative measurements of each nucleus.
• the preparation of the sample for this application is simple.
• NMR is a non-destructive technique that allows the sample to be recovered for other purposes. 13 C NMR methods are normally based on analysing the cluster of signals for the carbonyl carbons. Two clusters of signals are normally observed corresponding to acids in the sn 1,3- and 2-positions.
• Monoacidtriacylglycerols were purchased from Sigma Chemicals and Nu-Chek-Prep Inc:
• Tristearin (Tri-18:0)
• Triolein Tri-18:ln-9
• Trilinolein Tri-18:2n-6
• Trigammalinolenin (Tri- 18 : 3n-6)
• Trieicosenoin (Tri-20:ln-9)
• Trierucin (Tri-22:ln-9)
• Trinervonin (Tri-24:ln-9)
• the approximate number of scans collected for adequate signal-to-noise ranged from 300 to 1200 scans , depending on the complexity of the mixture.
• the total acquisition time for the experiments ranged between 1-4 h (Borage oil 1272 scans / 4h). Data points 65,536.
• the GLA carbonyl signals at the 2- and 1,3 -positions were well separated from all over carbonyl peaks in the spectra of the triacylglycerols. This allowed the ratio of 2- GLA / 1,3-GLA to be determined with reliability and precision in all cases.
• the method was validated by analysing a test mixture containing 8 triacylglycerols, including trigammalinolenin, of known proportions similar to those present in borage oil. Gross compositions had previously been determined by GLC. Two methods of calculation were employed. The first was a self-contained NMR method calculating the 2-GLA percentage as follows:
• Capsules D and B are sample capsules of provided in the clinical trial reported below.
• the NMR method can be used to give reliable analytical data for GLA at the sn-2 position. Indeed, it is particularly suited to borage oil because of the non-interference of other fatty acids present. Interestingly results from the NMR method are reported to agree with those from the older derivatisation-chromatographic ones. Our previous estimate (40%) derived from these older methods also agrees with the NMR results.
• Exclusion criteria include any form of steroid or immunosuppressive drug treatment, pregnancy, hyperlipidemia, regular use of aspirin or related drugs and vitamin or fatty acid supplementation within the previous three months.
• Supplementation was in the form of one gram oil capsules daily (5/day for low dose, 15/day high dose) for 18 months duration.
• Borage officinalis oil and omega-6 polyunsaturated fatty acids are food ingredients that are generally recognised as safe for human consumption (GRAS).
• GRAS safe for human consumption
• Clinical assessment included: Extended Disability Scale Scores (EDSS) and clinical relapse record. Venous blood (50 mis) was obtained for laboratory studies on the 1 st , 3 rd , 6 th , 12 th , 15 th , and 18 th month of supplementation.
• Soluble adhesion molecules in serum particularly ICAM-1 and VCAM-1 • Peripheral blood mononuclear cell membrane fatty acids and plasma phospholipid fatty acid composition.
• the primary outcome parameter was the number of clinical relapses between baseline (Month 0) and the end of treatment (Month 18). Secondary outcome parameters included: the time to first clinical relapse; severity of relapses, as assessed by EDSS score and the use of steroid treatment; and changes in EDSS at Month 3, 6, 9, 12, and 18 compared to baseline and defined as at least 1.0 point increase in the EDSS that is sustained for 3 months or at least 1.5 point increase on the EDSS from the baseline EDSS that is sustained for 3 months. As this trial did not receive external funding, it was not possible for financial reasons to evaluate MS diseases activity with magnetic resonance imaging. 1 of 3
• the first patient was a 48 year old woman who had had a clinically active, relapsing remitting MS for 9 years. She had originally worked as a full-time administrator at the local Health Authority, but she was unable to perform her duties because of her severe MS. Therefore, she later worked as a part-time secretary, but still had difficulties in mobilization because of muscles stiffness and sensory disturbances. She was also experiencing severe clinical relapses at an average of one relapse every nine months. Most of these relapses had resulted in hospital admissions for steroid therapy. In view of her active MS, she was recruited into the Borage oil trial. There were no adverse events relating to the study, and after taking the medication for four months, she experienced good improvement in her walking and sensory symptoms.
• Patient 2 f Control The second case was a 46-year old woman who also had a clinically active relapsing remitting MS for 8 years. She had originally worked as a shop assistant, but became unemployed after MS was diagnosed.
• the third case was a 26 year-old man who was diagnosed with definite MS in April 2001. His symptoms had started in 1999 when he complained of diffuse, intractable pain affecting various parts of his body, particularly the left side of the chest and abdomen. This was followed by intermittent numbness in the hands and feet, associated with fluctuating weakness. There were also distressing bladder symptoms in the form of urinary frequency and urgency.
• the diagnosis of MS in 2001 was based on his relapsing remitting symptoms, and was confirmed by positive cerebrospinal fluid analysis and magnetic resonance imaging (MRI) of the brain, which showed multiple white matter abnormalities in both cerebral hemispheres. Symptoms did not respond to various pharmaceutical therapies.
• MRI magnetic resonance imaging
• FGO Fungal Oil
• BOO Borage Oil
• EPO Evening Primrose Oil
• SAF Safflower Oil

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Mycology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Medical Informatics (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Emergency Medicine (AREA)
• Pain & Pain Management (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Psychiatry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (13)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=9958058

Family Applications (1)

Country Status (15)

Cited By (11)

Families Citing this family (15)

Citations (2)

Family Cites Families (126)

• 2003
  • 2003-05-14 GB GBGB0311081.4A patent/GB0311081D0/en not_active Ceased
• 2004
  • 2004-05-14 EP EP10195799A patent/EP2311450A1/en not_active Withdrawn
  • 2004-05-14 DE DE112004000762T patent/DE112004000762T5/de not_active Ceased
  • 2004-05-14 AU AU2004237936A patent/AU2004237936B2/en not_active Ceased
  • 2004-05-14 CN CNA2004800129820A patent/CN1901898A/zh active Pending
  • 2004-05-14 ES ES200550074A patent/ES2294914B2/es not_active Expired - Fee Related
  • 2004-05-14 GB GB0521395A patent/GB2415378B/en not_active Expired - Fee Related
  • 2004-05-14 CN CN2011103208135A patent/CN102512411A/zh active Pending
  • 2004-05-14 JP JP2006530503A patent/JP2006528233A/ja active Pending
  • 2004-05-14 US US10/555,757 patent/US7935729B2/en not_active Expired - Fee Related
  • 2004-05-14 CH CH01806/05A patent/CH699430B1/de not_active IP Right Cessation
  • 2004-05-14 CA CA2524036A patent/CA2524036C/en not_active Expired - Lifetime
  • 2004-05-14 WO PCT/GB2004/002089 patent/WO2004100943A1/en not_active Ceased
  • 2004-05-14 EP EP04733020A patent/EP1631280A1/en not_active Withdrawn
• 2005
  • 2005-10-21 IS IS8083A patent/IS8083A/is unknown
  • 2005-11-10 SE SE0502484A patent/SE531985C2/sv not_active IP Right Cessation
  • 2005-12-13 FI FI20051280A patent/FI122130B/fi not_active IP Right Cessation
  • 2005-12-14 NO NO20055937A patent/NO20055937L/no not_active Application Discontinuation
• 2011
  • 2011-03-10 JP JP2011053394A patent/JP2011144195A/ja active Pending
  • 2011-04-06 US US13/064,647 patent/US20110184063A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events